Chronic Lymphocytic Leukemia: Epidemiology Forecast to 2027

1.1 List of Tables
1.2 List of Figures

2.1 Related Reports
2.2 Upcoming Reports

3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources Used
3.4.2 Forecast Assumptions and Methods - Population
3.4.3 Forecast Assumptions and Methods - Diagnosed Incident Cases of CLL
3.4.4 Diagnosed Incident Cases by Stage at Diagnosis (Rai Staging and Modified Rai Staging)
3.4.5 Diagnosed Incident Cases by Stage at Diagnosis (Binet Staging)
3.4.6 High-Risk Cytogenetics (11q Deletion, 13q Deletion, 17p Deletion, p53 mutation, CD38, ZAP70 and IGHV [Unmutated]) Among the Diagnosed Incident Cases of CLL
3.4.7 Forecast Assumptions and Methods - Diagnosed Prevalent Cases of CLL
3.5 Epidemiological Forecast for CLL (2017-2027)
3.5.1 Diagnosed Incident Cases of CLL
3.5.2 Age-Specific Diagnosed Incident Cases of CLL
3.5.3 Sex-Specific Diagnosed Incident Cases of CLL
3.5.4 Diagnosed Incident Cases of CLL by Rai Stage at Diagnosis
3.5.5 Diagnosed Incident Cases of CLL by Modified Rai Stage at Diagnosis
3.5.6 Diagnosed Incident Cases of CLL by Binet Stage at Diagnosis
3.5.7 Diagnosed Incident Cases of CLL by High-Risk Cytogenetics
3.5.8 Diagnosed Prevalent Cases of CLL
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis

4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About
4.4 Contact Us
4.5 Disclaimer

Table 1: Risk Factors and Comorbid Conditions Associated with CLL
Table 2: 7MM, Diagnosed Incident Cases of CLL by High-Risk Cytogenetics, Both Sexes, Ages =18 Years, N, 2017

Figure 1: 7MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages =18 Years, N, 2017 and 2027
Figure 2: 7MM, Diagnosed Prevalent Cases of CLL, Both Sexes, Ages =18 Years, N, 2017 and 2027
Figure 3: 7MM, Age-Standardized Diagnosed Incidence of CLL (Cases per 100,000 Population), Men, Ages =18 Years, 2017-2027
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of CLL (Cases per 100,000 Population), Women, Ages =18 Years, 2017-2027
Figure 5: 7MM, Sources Used, Diagnosed Incident Cases of CLL
Figure 6: 7MM, Sources Used, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Rai Staging and Modified Rai Staging)
Figure 7: 7MM, Sources Used, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Binet Staging)
Figure 8: 7MM, Sources Used, 11q and 13q Deletion Among the Diagnosed Incident Cases of CLL
Figure 9: 7MM, Sources Used, 17p Deletion Among the Diagnosed Incident Cases of CLL
Figure 10: 7MM, Sources Used, TP53 Among the Diagnosed Incident Cases of CLL
Figure 11: 7MM, Sources Used, CD38 Among the Diagnosed Incident Cases of CLL
Figure 12: 7MM, Sources Used, ZAP70 Among the Diagnosed Incident Cases of CLL
Figure 13: 7MM, Sources Used, IGHV (Unmutated) Among the Diagnosed Incident Cases of CLL
Figure 14: 7MM, Sources Used, Diagnosed Prevalent Cases of CLL
Figure 15: 7MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages =18 Years, N, 2017
Figure 16: 7MM, Age-Specific Diagnosed Incident Cases of CLL, Both Sexes, N, 2017
Figure 17: 7MM, Sex-Specific Diagnosed Incident Cases of CLL, Ages =18 Years, N, 2017
Figure 18: 7MM, Diagnosed Incident Cases of CLL by Rai Stage at Diagnosis, Both Sexes, Ages =18 Years, N, 2017
Figure 19: 7MM, Diagnosed Incident Cases of CLL by Modified Rai Stage at Diagnosis, Both Sexes, Ages =18 Years, N, 2017
Figure 20: 7MM, Diagnosed Incident Cases of CLL by Binet Stage at Diagnosis, Both Sexes, Ages =18 Years, N, 2017
Figure 21: 7MM, Diagnosed Prevalent Cases of CLL, Both Sexes, Ages =18 Years, N, 2017